Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2010.0126
REVIEW
|
Decision-making treatment for early breast cancer and future perspectives.
|
|
Affiliation: Dimosthenis Ziogas M.D., Department of Surgery, University of Ioannina , School of Medicine , 45110 Ioannina , Greece .
E-mail: deziogas@hotmail.com |
ABSTRACT
Currently decision-making for the treatment of women with early, node-negative breast cancer is based on age, tumor size, grade, estrogen receptor (ER) status and HER2 status. However, about 30% of these patients receiving an unnecessary systemic chemotherapy and another substantial proportion an inadequate treatment with intrinsic or acquired resistance. More recently, to improve these decisions the multigene assays 21-gene (Oncotype DX) and 70-gene signature (MammaPrint) and the isolated tumor cells (ITCs) in sentinel lymph node(s) are proposed.
In this review article, the advantages and limitations of these new markers are discussed and considering a balance of risks and benefits a treatment approach is suggested. Moreover, the potential of molecular networks research to develop novel biomarkers for improving a tailored breast cancer treatment is also described.
|
|
| You can have an online full-text access and a PDF of this article: |
- Either purchase this paper for €33 EUR. Please, click here
|
|
- Or through one year subscription PayPal
|
|
Online
ISSN : 1109 - 7647
Print ISSN : 1109 - 7655
 We
subscribe to the HONcode principles. Verify
here.
please, read our policy about privacy
and confidentiality of information and transparency
of sponsorship
last
update: 6 March 2010 |
|
